JP2019513355A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513355A5
JP2019513355A5 JP2018549545A JP2018549545A JP2019513355A5 JP 2019513355 A5 JP2019513355 A5 JP 2019513355A5 JP 2018549545 A JP2018549545 A JP 2018549545A JP 2018549545 A JP2018549545 A JP 2018549545A JP 2019513355 A5 JP2019513355 A5 JP 2019513355A5
Authority
JP
Japan
Prior art keywords
food product
food
composition
laxatives
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018549545A
Other languages
Japanese (ja)
Other versions
JP2019513355A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/024606 external-priority patent/WO2017172816A1/en
Publication of JP2019513355A publication Critical patent/JP2019513355A/en
Publication of JP2019513355A5 publication Critical patent/JP2019513355A5/ja
Pending legal-status Critical Current

Links

Claims (33)

個体の便秘症の処置で使用するための食品であって、
前記食品が、
１つ以上の食品成分、および、
１つ以上の下剤を含み、
ここで、個体による食品の摂取によって、個体の腸管運動を引き起こし、それ故、個体の便秘症を軽減し、
前記食品が、常温保存可能な包装された固体食品を含む、食品。 A food for use in the treatment of constipation in an individual, comprising:
The food is
One or more food ingredients, and
Contains one or more laxatives,
Here, ingestion of food by the individual causes intestinal motility of the individual, thus reducing constipation of the individual,
A food product, wherein the food product includes a packaged solid food product that can be stored at room temperature . １つ以上の下剤が、リン酸二ナトリウム、クエン酸マグネシウム、水酸化マグネシウム（マグネシア乳）、硫酸マグネシウム（エプソム塩）、リン酸一ナトリウム、二リン酸ナトリウム、ラクツロース、ポリエチレングリコール（ＰＥＧ）、ビタミンＣ、スルホコハク酸ジオクチル（ドクセート）、ビサコジル（Ｄｕｌｃｏｌａｘ）、ヒマシ油、およびソルビトールのいずれかを含む、請求項１に記載の食品。 One or more laxatives are disodium phosphate, magnesium citrate, magnesium hydroxide (magnesia milk), magnesium sulfate (epsom salt), monosodium phosphate, sodium diphosphate, lactulose, polyethylene glycol (PEG), vitamins The food product according to claim 1, comprising any one of C, dioctyl sulfosuccinate (doxate), biscodyl, castor oil, and sorbitol. ＰＥＧが、１７グラム以下の量のＰＥＧ３３５０を含む、請求項２に記載の食品。 The food product of claim 2, wherein the PEG comprises PEG 3350 in an amount of 17 grams or less. １つ以上の食品成分が、１つ以上の下剤と一緒に混合される、請求項１に記載の食品。 One or more food ingredients, are mixed together with one or more laxatives, food product of claim 1. １つ以上の下剤が、食品のコーティングを含む、請求項１に記載の食品。 The food product of claim 1, wherein the one or more laxatives comprises a coating of the food product . 個体の腸管運動が、１つ以上の下剤の摂取の１２時間以内に引き起こされる、請求項１に記載の食品。 The food product of claim 1, wherein the intestinal motility of the individual is caused within 12 hours of ingestion of one or more laxatives. 個体の腸管運動が、２４時間以内に引き起こされる、請求項１に記載の食品。 The food product of claim 1, wherein the intestinal motility of the individual is caused within 24 hours. 食品が、インスタントの食品バーを含む、請求項１に記載の食品。 The food product of claim 1, wherein the food product comprises an instant food bar. 食品が、フレーバリングを有する又はフレーバリングのない、および液体と混合されるように構成された、食用粉末を含む、請求項１に記載の食品。 2. The food product of claim 1, wherein the food product comprises an edible powder with or without flavoring and adapted to be mixed with a liquid. 個体が薬剤を使用し、その副作用が便秘症である、請求項１に記載の食品。 The food according to claim 1, wherein the individual uses the drug and its side effect is constipation. 薬剤がオピオイドを含む、請求項１０に記載の食品。 The food product of claim 10, wherein the drug comprises an opioid. オピオイドが、モルヒネ、コデイン、オキシコドン、およびジラウジッドの１つ以上を含む、請求項１１に記載の食品。 12. The food product of claim 11, wherein the opioid comprises one or more of morphine, codeine, oxycodone, and dilauzide. 薬剤が抗うつ薬を含む、請求項１０に記載の食品。 11. The food product of claim 10, wherein the drug comprises an antidepressant drug. 抗うつ薬が、アミトリプチリンおよびイミプラミンの１つ以上を含む、請求項１３に記載の食品。 14. The food product of claim 13, wherein the antidepressant drug comprises one or more of amitriptyline and imipramine. 薬剤が抗痙攣薬を含む、請求項１０に記載の食品。 The food product of claim 10, wherein the drug comprises an anticonvulsant. 抗痙攣薬が、フェニトインおよびカルバマゼピンの１つ以上を含む、請求項１５に記載の食品。 16. The food product of claim 15, wherein the anticonvulsant comprises one or more of phenytoin and carbamazepine. 薬剤が鉄サプリメントを含む、請求項１０に記載の食品。 The food product of claim 10, wherein the drug comprises an iron supplement. 薬剤がカルシウムチャネル遮断薬を含む、請求項１０に記載の食品。 11. The food product of claim 10, wherein the drug comprises a calcium channel blocker. カルシウムチャネル遮断薬が、１つ以上のジルチアゼムおよびニフェジピンを含む、請求項１８に記載の食品。 19. The food product of claim 18, wherein the calcium channel blocker comprises one or more diltiazem and nifedipine. 便秘症が、２４時間以上の持続時間の間続いた、請求項１に記載の食品。 The food product of claim 1, wherein constipation has persisted for a duration of 24 hours or more. 食品が食事を含む、請求項１に記載の食品。 The food product of claim 1, wherein the food product comprises a meal. １つ以上の下剤が、食品の総重量の５０重量％以上である、請求項１に記載の食品。 The food product of claim 1, wherein the one or more laxatives is 50% or more by weight of the total food product . １つ以上の下剤；および
１つ以上の食品成分、を含む組成物であって、
ここで下剤が、１つ以上の食品成分と組み合わされ、１つ以上の食品成分は、組成物が個体によって摂取されるときに、１つ以上の下剤が個体の結腸内に放出される程度まで１つ以上の食品成分が消化されるような、量またはタイプのいずれかである、組成物。 A composition comprising one or more laxatives; and one or more food ingredients,
Where the laxative is combined with one or more food ingredients, the one or more food ingredients to the extent that the one or more laxatives are released into the colon of the individual when the composition is ingested by the individual. A composition, either in amount or type, such that one or more food ingredients are digested. １つ以上の下剤が、ポリエチレングリコール（ＰＥＧ）３３５０を含む、請求項２３に記載の組成物。   24. The composition of claim 23, wherein the one or more laxatives comprises polyethylene glycol (PEG) 3350. ＰＥＧ３３５０が、１７グラム以下の量を含む、請求項２３に記載の組成物。   24. The composition of claim 23, wherein PEG3350 comprises an amount of 17 grams or less. １つ以上の食品成分が、１つ以上の下剤と一緒に混合される、請求項２３に記載の組成物。   24. The composition of claim 23, wherein one or more food ingredients are mixed together with one or more laxatives. １つ以上の食品成分が、組成物のコーティングを含む、請求項２３に記載の組成物。   24. The composition of claim 23, wherein the one or more food ingredients comprises a coating of the composition. 個体の腸管運動が、組成物の摂取の１２時間以内に引き起こされる、請求項２３に記載の組成物。   24. The composition of claim 23, wherein intestinal motility of the individual is caused within 12 hours of ingestion of the composition. インスタントの食品バーを含む、請求項２３に記載の組成物。   24. The composition of claim 23, comprising an instant food bar. レディ・トゥ・ドリンクのシェイクを含む、請求項２３に記載の組成物。   24. The composition of claim 23, comprising a ready-to-drink shake. 液体と混合されるように構成された食用粉末を含む、請求項２３に記載の組成物。   24. The composition of claim 23, which comprises an edible powder adapted to be mixed with a liquid. 食事を含む、請求項２３に記載の組成物。   24. The composition of claim 23, which comprises a meal. １つ以上の下剤が、組成物の総重量の５０重量％以上である、請求項２３に記載の組成物。   24. The composition of claim 23, wherein the one or more laxatives is 50% or more by weight of the total composition.
JP2018549545A 2016-03-29 2017-03-28 Preparation for treating constipation Pending JP2019513355A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314883P 2016-03-29 2016-03-29
US62/314,883 2016-03-29
PCT/US2017/024606 WO2017172816A1 (en) 2016-03-29 2017-03-28 Formulations for treating constipation

Publications (2)

Publication Number Publication Date
JP2019513355A JP2019513355A (en) 2019-05-30
JP2019513355A5 true JP2019513355A5 (en) 2020-05-07

Family

ID=59966423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549545A Pending JP2019513355A (en) 2016-03-29 2017-03-28 Preparation for treating constipation

Country Status (8)

Country Link
EP (1) EP3436011A4 (en)
JP (1) JP2019513355A (en)
KR (1) KR20180123136A (en)
CN (1) CN109475544A (en)
AU (1) AU2017241904A1 (en)
CA (1) CA3018589A1 (en)
IL (1) IL261958A (en)
WO (1) WO2017172816A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360423A1 (en) * 2018-01-12 2020-11-19 Colonaryconcepts Llc Solid concentrated constipation treatment formulations
WO2019140319A1 (en) * 2018-01-12 2019-07-18 Colonaryconcepts Llc Constipation specific treatment formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232699A (en) * 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
US5234916A (en) * 1992-06-12 1993-08-10 The Proctor & Gamble Company Psyllium drink mix compositions
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
WO2006122104A1 (en) * 2005-05-06 2006-11-16 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
CN101002832B (en) * 2006-09-02 2011-01-05 江西农业大学 Granulated quickly dissolving medicine for relaxing bowel
CN101589806A (en) * 2008-05-29 2009-12-02 北京亿利高科生物工程技术研究所有限公司 A kind of solid low-energy food that is rich in dietary fiber and polyethylene glycol and preparation method thereof
US9655919B2 (en) * 2008-07-09 2017-05-23 The General Hospital Corporation Methods and compositions for bowel cleansing before a medical procedure
US20120107430A1 (en) * 2009-05-01 2012-05-03 Jeffery Dale Scott Pre-procedure meal regimen
JP2014532725A (en) * 2011-11-06 2014-12-08 エスエスブイ セラピューテクス，リミティド ライアビリティ カンパニー Concentrated prunes and prebiotic formulations as laxatives and food supplements
CA2859203C (en) * 2011-12-19 2020-08-25 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
JP6726964B2 (en) * 2012-08-21 2020-07-22 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal tract diseases
WO2014032108A1 (en) * 2012-08-29 2014-03-06 Borody Thomas J Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
AU2015253178B2 (en) * 2014-04-29 2020-03-12 Colonaryconcepts Llc Foods, systems, methods, and kits for providing electrolyte replacement
CN108024975A (en) * 2015-09-01 2018-05-11 科罗纳里康赛普茨有限责任公司 Charthartic preparation and its preparation

Similar Documents

Publication Publication Date Title
HRP20161792T1 (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
ES2703051T3 (en) Compositions of matrix and layer for the protection of bioactive agents
JP2019513355A5 (en)
KR101862091B1 (en) Method of producing enteric soft capsule
RU2005121665A (en) PREBIOTIC COMPOSITIONS
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
CN102178161A (en) Green tea noodles
JP2008516998A5 (en)
RU2009115791A (en) MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE
RU2015122255A (en) CHITIN OR ITS DERIVATIVES FOR PREVENTION AND / OR TREATMENT OF PARASITIC DISEASES
JP7206223B2 (en) Substances for prophylactic and/or supportive treatment of Parkinson's disease
WO2019074214A9 (en) Colonic purgative composition containing sulfates
JP2015533484A5 (en)
RU2018101220A (en) PRODUCT BASED ON IRON BIS-GLYCINATE CHELATE AND ALGINIC ACID AND / OR ITS WATER-SOLUBLE SALTS, ITS COMPOSITION AND ITS PHARMACEUTICAL APPLICATIONS
WO2013098268A3 (en) Tablets and dry-coated agents
HRP20231691T1 (en) Composition for use in the treatment of intestinal alterations
TW201121435A (en) Drink or food composition for weight loss.
CN109303873A (en) The prescription of one group for the treatment of oedema
WO2011100668A4 (en) Methods and compositions of civamide to treat diseases of the intestines
CN104224893A (en) Absorbable encapsulated calcium in hypromellose capsule
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
EP2749288A3 (en) Capsule and composition comprising seed oil
RU2020102020A (en) THERAPEUTIC APPLICATION Lactobacillus plantarum
RU2016140409A (en) Solid galenic preparation
MX2020007927A (en) Use of functionalized calcium carbonate as active ingredient.